H emifacial spasm presents as an involuntary contraction of the muscles on either side of the face, 1 which occurs secondary to compression of the facial nerve by a vascular loop at the root exit zone. 4, 5 Traditionally, HFS treatment includes several approaches such as anticonvulsant medications, and chemical or nerve decompression. Among them, the retromastoid craniotomy and facial nerve MVD has been proven to be an effective cure for patients. 17, 24, 27 Since the use of botulinum neurotoxin in HFS was approved by the US FDA in 1989, it has been used as a minimally invasive treatment option for HFS. 12 Botulinum neurotoxin type A, the most commonly used botulinum neurotoxin for HFS, produces muscle atrophy that only persists for 3-4 months, so almost all of these patients undergo multiple injections prior to MVD. Although it is not curative, some practitioners, and patients with HFS, prefer botulinum neurotoxin injection therapy. So far, very little has been published regarding the effect of previous botulinum neurotoxin treatment on MVD for HFS. In the present study, the main objective was to investigate the characteristics, outcomes, and complications of MVD for HFS after previous botulinum neurotoxin treatment.
Methods

Study Design
A retrospective study was conducted with institutional review board approval from the University of Effect of previous botulinum neurotoxin treatment on microvascular decompression for hemifacial spasm Pittsburgh. Of 293 patients with typical HFS, 176 with HFS received botulinum neurotoxin injection treatment prior to regular single MVD (Group I), and 70 patients underwent their first MVD but had no previous botulinum neurotoxin treatment (Group II). Clinical outcome data were obtained immediately after the operation, at discharge, and at follow-up. Follow-up was performed by contacting the patients by telephone during June of 2008. Follow-up data were collected from 177 patients who had a minimum follow-up period of 9 months (mean 54.48 ± 27.84 months).
Microvascular Decompression
We reviewed the records of patients who had HFS and underwent MVD procedures at the University of Pittsburgh Medical Center between January 1, 2000, and December 31, 2007. The operation was performed using a routine retrosigmoid approach. 16, 19 Short-acting neuromuscular junction blocking medications were used for intubation. No additional paralytic agent was administered during EMG monitoring. The dissection was begun from the caudal cranial nerves, using withdrawal of CSF and gentle exposure of pertinent anatomy with handheld suction. Following careful exposure of the cranial nerve VII-VIII complex, any suspect arteries or veins compressing cranial nerve VII anywhere from the brainstem to beyond the root exit zone were treated. The operation was complete when the nerve no longer demonstrated any visible evidence of vascular compression. After confirming that there were no further offending vessels, the surgeon terminated the procedure and closed the craniotomy in a routine fashion.
Intraoperative Neurophysiological Monitoring and Alarm Criteria
Lateral spread response is a delayed abnormal muscle response in the mentalis muscle following stimulation of the zygomatic branch of the facial nerve. 27 During surgery, free-run EMG monitoring of the facial, glossopharyngeal, and vagus nerves was performed, in addition to LSR. All instances of free-run EMG activity, regardless of type (spikes, bursts, and neurotonic discharges), were made audible to and also immediately reported to the surgeon and recorded in the patient record. Auditory nerve function was monitored using brainstem auditory evoked potentials, performed with our institution's alarm criteria. 23 Physician oversight and interpretation of neurophysiological responses (such as brainstem auditory evoked potentials, lateral spread responses, and electromyography from cranial nerves) was performed using a combined on-site and remote model used by the University of Pittsburgh Medical Center. 26 
Statistical Analysis
Statistical analyses were performed using SAS version 9.1.2 (SAS Institute). Continuous variables were presented as mean ± SD and categorical variables as frequency (%). Group differences in demographics, clinical characteristics, and outcomes were assessed using chisquare tests, using the Fisher exact test correction when needed. A p value ≤ 0.05 was considered statistically significant.
Results
Demographics
Two hundred forty-six patients with HFS were reviewed. The mean patient age was 52.25 ± 12.07 years (range 17-82 years), with a female:male ratio of 1.8:1 and left:right HFS ratio of 1.2:1. Medical and surgical histories were obtained from each patient undergoing MVD. One hundred and seventy-six patients (71.54%) received prior botulinum neurotoxin treatment (Group I). In Group I, multiple botulinum neurotoxin treatments were administered to 158 patients with HFS, and the mean duration of improvement per application was 4.5 months. The mean interval from beginning the botulinum neurotoxin application to undergoing MVD was approximately 4 years, and the mean frequency of botulinum neurotoxin injections was approximately 3 per year.
Preoperative Characteristics
A greater number of patients with facial weakness, tinnitus, tonus, and platysmal involvement were found in Group I as compared with Group II. A significantly greater number of patients had HFS on the left side in Group II than those in Group I. There were no significant statistical differences in any of the other clinical characteristics (such as sex, decreased corneal reflex, decreased hearing, and others) between the 2 groups (Table 1) .
Intraoperative LSR Monitoring
Data regarding intraoperative monitoring of the LSR during MVD were available for 229 (93.09%) of the 246 patients. The LSR disappeared in 101 (60.48%) of the 167 patients in Group I as compared with 46 (74.19%) of the 62 patients in Group II (p = 0.054; Table 2 ).
Compressing Vasculature Observed Intraoperatively
The vessels compressing the root exit zone as identified by the surgeon are summarized in Table 2 . A majority (70.5%) of patients had multiple compressing vessels. The compression was commonly caused by the AICA, PICA, VA, and some veins in both groups. A significantly greater number of patients had the PICA and VA as the offending vessels intraopertively in Group II as compared with Group I (p = 0.008 and p = 0.005, respectively; Table 2 ).
Operative Outcomes
In 176 patients (Group I), 91.48% experienced immediate postoperative relief of spasm, 92.61% experienced relief at the time of discharge, and 90.40% had relief at the follow-up period. No significant difference in spasm relief between the 2 groups was observed at the immediate postoperative, discharge, or follow-up stages (Table 2) .
Postoperative Complications
Postoperative complications were observed in both patient groups (Table 3) . Complications included hearing loss, balance disorder, CSF leakage, diplopia, headache, and dizziness/vertigo. Three patients had new facial palsy in Group I, which was not documented during the pre- 
Discussion
The use of botulinum neurotoxin type A in HFS was approved by the US FDA in 1989, and since then, in view of growing evidence supporting its efficacy, it has become a standard treatment for HFS. 2, 8 As previously reported in the literature by Barbosa et al., 2 from 1993 to 2004 a total of 808 injections with botulinum neurotoxin were administered to 54 patients with HFS. The mean duration of improvement per application was 3.46 months and the mean rate of improvement using subjective judgment by the patient was 83%. Botulinum neurotoxin, although a less invasive treatment than surgery, can result in potentially life-threatening allergic reactions and systemic manifestation of toxin adverse effects. 3, 7 Because HFS is a disabling condition, the choice to receive repeated noninvasive local injections of botulinum neurotoxin appears to be more acceptable before MVD surgery is considered. In the present study, we analyzed and compared 2 patients groups, one that underwent botulinum neurotoxin treatment prior to MVD, and another that did not.
Although botulinum neurotoxin is a therapeutic alternative for HFS, it has some unavoidable transitory side effects, such as mild facial paresis (lagophthalmos or lower facial paralysis), ptosis, diplopia, and ecchymosis, disappearing after days or weeks. 2, 12 In our series, there were significantly more patients with preoperative facial weakness in Group I than in Group II. There was a greater number of patients with left HFS in Group II than in Group I, which was inconsistent with the results previously reported by Revuelta-Gutiérrez et al. 21 In addition, our data reveal a higher incidence of patients with platysma muscle involvement and tonus in the facial muscles, when compared with people with HFS not treated by previous botulinum neurotoxin. 22, 27 More than half of the patients in Group I had platysmal involvement and tonus simultaneously. Although the exact origin of the platysmal involvement or tonus has not been studied or evaluated, it is possible that previous treatment with botulinum neurotoxin could be a cause of platysmal involvement or tonus according to the study. In addition, there were significant differences in preoperative tinnitus in Group I as compared with Group II (p = 0.01).
Microvascular decompression is a highly accepted and effective method for treatment of patients with HFS. 1, 4, 29 Much has been published regarding the high efficacy of MVD for HFS, with cure rates ranging anywhere from approximately 82% to 92%, and excellent long-term results 10 years after MVD in 84% of patients. 25, 30 Hemifacial spasm is caused by vascular compression of the root exit zone of the facial nerve. 6, 20 The compression was commonly caused by the AICA, PICA, VA, or some veins or perforators in both groups. In our data, it is interesting that there was a high incidence of the PICA and VA as offending vessels in Group II as compared with Group I.
Based on the spasm relief during the immediate postoperative period, results indicate that intraoperative monitoring is an effective tool in helping identify offending vessels during repeat MVD.
14,27 Given the significant negative predictive value of LSR monitoring, the surgeon can be reassured that an adequate decompression has been achieved and avoid unnecessary operation time and resultant complications, especially when multiple vessels are involved. 9, 15, 18, 28 The loss of LSR after MVD was not significantly different between the groups. In our previous study we found that HFS patients treated with botulinum neurotoxin prior to MVD demonstrated higher LSR baseline amplitudes during intraoperative monitoring. 12 These data could be related to muscle poly-reinnervation after recovery from repeated botulinum neurotoxin use. Based on our previously published results 27 and the current study, the use of LSR in MVDs may be very valuable, irrespective of botulinum neurotoxin treatment.
The operative complications of MVD for HFS include new or worsening facial weakness, hearing loss, diplopia, headache, balance problem, and CSF leakage. 10, 13, 14 In our study there was no significant difference in postoperative complications between the 2 groups, consistent with results previously reported. 12 Based on our data, MVD is an effective and safe procedure for patients with HFS previously treated by botulinum neurotoxin. Study limitations include retrospective analysis of data and lack of objective evaluation of long-term data.
Conclusions
Microvascular decompression is an effective and safe procedure for patients with HFS previously treated by botulinum neurotoxin. Intraoperative monitoring with LSR is an effective tool for evaluating adequate decompression.
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